Pharmacy Trends
Protecting Your Clients Against Off-Label Ozempic
Biosimilars, GLP-1s, and Stop-loss: Topics Benefit Advisors Need to Consider in Q3 2023
Everything you need to know about 340B in 2023
The 5 Most Expensive Gene Therapies in the U.S.
State Legislation Trends Every Benefit Advisor Should Be Tracking in 2023
Prepare Your Clients for the Unpredictable
Economic Downturn and High-Cost Specialty Claims Keep Plan Sponsors Up At Night
What Benefits Advisors from All States Can Learn from Oklahoma
Enjoy our latest blogs, white papers and news by signing up for our newsletter today!
